Cibc World Market Inc. Has $28.10 Million Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Cibc World Market Inc. reduced its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 8.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 54,018 shares of the medical research company’s stock after selling 4,737 shares during the quarter. Cibc World Market Inc.’s holdings in Thermo Fisher Scientific were worth $28,102,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Legacy Investment Solutions LLC acquired a new position in Thermo Fisher Scientific in the third quarter worth about $26,000. Peterson Financial Group Inc. acquired a new position in shares of Thermo Fisher Scientific in the 3rd quarter worth approximately $27,000. Missouri Trust & Investment Co acquired a new stake in Thermo Fisher Scientific in the 4th quarter valued at $29,000. Endeavor Private Wealth Inc. acquired a new position in Thermo Fisher Scientific during the fourth quarter worth $30,000. Finally, Decker Retirement Planning Inc. bought a new position in shares of Thermo Fisher Scientific during the fourth quarter valued at $43,000. Institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Trading Down 1.4 %

TMO opened at $598.40 on Friday. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.26 and a current ratio of 1.63. Thermo Fisher Scientific Inc. has a twelve month low of $493.30 and a twelve month high of $627.88. The firm’s fifty day moving average is $539.66 and its two-hundred day moving average is $570.59. The firm has a market cap of $228.89 billion, a PE ratio of 37.52, a price-to-earnings-growth ratio of 3.89 and a beta of 0.76.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.49% and a net margin of 14.48%. Equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 21.69 EPS for the current year.

Thermo Fisher Scientific declared that its board has authorized a share repurchase plan on Friday, November 15th that allows the company to repurchase $4.00 billion in shares. This repurchase authorization allows the medical research company to reacquire up to 2% of its shares through open market purchases. Shares repurchase plans are usually an indication that the company’s management believes its shares are undervalued.

Thermo Fisher Scientific Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Wednesday, January 15th. Stockholders of record on Friday, December 13th were issued a $0.39 dividend. This represents a $1.56 annualized dividend and a dividend yield of 0.26%. The ex-dividend date of this dividend was Friday, December 13th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 9.78%.

Insider Buying and Selling

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 9,000 shares of the company’s stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $552.86, for a total transaction of $4,975,740.00. Following the completion of the transaction, the chief executive officer now owns 14,608 shares of the company’s stock, valued at $8,076,178.88. This represents a 38.12 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Insiders have sold a total of 29,000 shares of company stock worth $15,859,540 over the last ninety days. Company insiders own 0.34% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on TMO shares. Robert W. Baird dropped their target price on shares of Thermo Fisher Scientific from $632.00 to $622.00 and set an “outperform” rating for the company in a research report on Thursday, October 24th. UBS Group lifted their target price on shares of Thermo Fisher Scientific from $700.00 to $715.00 and gave the company a “buy” rating in a research note on Friday. Scotiabank started coverage on Thermo Fisher Scientific in a report on Monday, December 23rd. They set a “sector perform” rating and a $605.00 price target for the company. Redburn Atlantic initiated coverage on Thermo Fisher Scientific in a report on Monday, October 14th. They set a “buy” rating and a $680.00 target price on the stock. Finally, Bank of America cut their price target on Thermo Fisher Scientific from $675.00 to $660.00 and set a “buy” rating for the company in a report on Friday, December 13th. Four research analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $655.64.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.